Xiaobin Wu Sells 1,357 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,357 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $266.76, for a total value of $361,993.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The shares were sold at an average price of $261.20, for a total value of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The stock was sold at an average price of $269.37, for a total value of $399,745.08.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $270.15 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The firm has a market cap of $29.64 billion, a P/E ratio of 60.44 and a beta of 0.49. The stock’s 50-day moving average is $295.32 and its 200-day moving average is $312.15.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion during the quarter. Sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

Several institutional investors have recently bought and sold shares of ONC. Bank of America Corp DE bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $67,657,000. Man Group plc bought a new stake in shares of BeOne Medicines in the second quarter worth $59,031,000. Capital International Investors lifted its position in shares of BeOne Medicines by 3.3% in the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after purchasing an additional 161,052 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in BeOne Medicines during the second quarter worth $38,337,000. Finally, First Trust Advisors LP boosted its holdings in BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ONC. Leerink Partners upped their price target on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Morgan Stanley restated an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Barclays upped their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Truist Financial reiterated a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.